Masimo (MASI): Is the Current Share Price a Value Opportunity for Investors?

Masimo (MASI) shares have drifted lower over the past month, continuing a downward trend that has seen the stock lose about 13% over the past 3 months. Recent performance has investors reconsidering the current valuation.

See our latest analysis for Masimo.

Masimo’s share price has steadily slid this year as investors weigh weaker revenue growth against a sharp improvement in profitability, putting momentum under pressure. Over the past year, while the 12-month share price return has lagged, the total shareholder return sits at -2.5%, which has helped soften the blow for long-term holders.

If you’re looking for more opportunities in medtech and healthcare, check out our curated picks in the See the full list for free..

With Masimo trading well below its analyst price target, investors may wonder whether recent headwinds have set the stage for an undervalued entry point or if the current price fully reflects the company’s growth prospects.

Most Popular Narrative: 25% Undervalued

With Masimo closing at $140.65, the most popular narrative puts fair value at $187.57, significantly above the latest share price. The story centers on a dynamic mix of market expansion, new technologies, and a reenergized leadership team, factors expected to influence both revenue and earnings trajectories.

The expansion of dedicated specialty sales teams and realignment of the commercial structure is expected to drive increased market share in high-growth categories like capnography, brain monitoring, and hemodynamics. In these areas, current share is below 20%, which should accelerate top-line revenue growth and elevate long-term earnings.

Read the complete narrative.

Curious how analysts have mapped out Masimo’s potential? Find out what aggressive growth rates and ambitious profit jumps are included in this valuation target. Unlock the detailed roadmap fueling this provocative price forecast.

Result: Fair Value of $187.57 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, ongoing exposure to shifting global tariffs and heavy reliance on hospital contracts could undermine profitability and delay the company's anticipated recovery.

Find out about the key risks to this Masimo narrative.

Build Your Own Masimo Narrative

If you see the story differently or want your own take, dive into the numbers and craft a custom view in just a few minutes with Do it your way.

A great starting point for your Masimo research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

Don’t let unique opportunities pass you by. Power up your portfolio by filtering for the companies shaping tomorrow’s markets across technology, healthcare, and beyond.

• Spot real potential with these 3590 penny stocks with strong financials offering robust financials and market-beating resilience that could surprise the mainstream crowd.
• Catalyze your gains by targeting these 22 dividend stocks with yields > 3% with yields above 3%, combining steady income with portfolio growth for the long run.
• Get ahead of the curve and target high-growth disruptors through these 26 AI penny stocks leading advancements in artificial intelligence, automation, and predictive analytics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com